Exact Mass: 355.248436

Exact Mass Matches: 355.248436

Found 184 metabolites which its exact mass value is equals to given mass value 355.248436, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

   

Pipercide

(2E,4E,10E)-11-(2H-1,3-Benzodioxol-5-yl)-N-(2-methylpropyl)undeca-2,4,10-trienimidate

C22H29NO3 (355.2147324)


Alkaloid from the aerial parts of Piper retrofractum (Javanese long pepper) and the fruits of Piper nigrum (pepper). Pipercide is found in herbs and spices and pepper (spice). Pipercide is found in herbs and spices. Pipercide is an alkaloid from the aerial parts of Piper retrofractum (Javanese long pepper) and the fruits of Piper nigrum (pepper). Pipercide is a member of benzodioxoles. Pipercide is a natural product found in Piper mullesua, Piper retrofractum, and other organisms with data available.

   

3,4-dimethylidenenonanedioylcarnitine

3-[(8-carboxy-3,4-dimethylideneoctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H29NO6 (355.19947740000003)


3,4-dimethylidenenonanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylidenenonanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-dimethylidenenonanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-dimethylidenenonanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodeca-6,9-dienoylcarnitine

3-[(3-hydroxydodeca-6,9-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


3-Hydroxydodeca-6,9-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-Hydroxydodeca-6,9-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodeca-6,9-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodeca-6,9-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodeca-5,7-dienoylcarnitine

3-[(3-hydroxydodeca-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


3-Hydroxydodeca-5,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-Hydroxydodeca-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodeca-5,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodeca-5,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Hydroxydodeca-7,9-dienoylcarnitine

3-[(5-hydroxydodeca-7,9-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


5-Hydroxydodeca-7,9-dienoylcarnitine is an acylcarnitine. More specifically, it is an 5-Hydroxydodeca-7,9-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Hydroxydodeca-7,9-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Hydroxydodeca-7,9-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxydodeca-7,10-dienoylcarnitine

3-[(3-hydroxydodeca-7,10-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


3-Hydroxydodeca-7,10-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-Hydroxydodeca-7,10-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxydodeca-7,10-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxydodeca-7,10-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxydodeca-5,8-dienoylcarnitine

3-[(2-hydroxydodeca-5,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


2-Hydroxydodeca-5,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an 2-Hydroxydodeca-5,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxydodeca-5,8-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxydodeca-5,8-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Hydroxydodeca-8,10-dienoylcarnitine

3-[(6-Hydroxydodeca-8,10-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C19H33NO5 (355.23586080000007)


6-Hydroxydodeca-8,10-dienoylcarnitine is an acylcarnitine. More specifically, it is an 6-Hydroxydodeca-8,10-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Hydroxydodeca-8,10-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Hydroxydodeca-8,10-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(6E,10E)-3-Hydroxydodeca-6,10-dienoylcarnitine

3-[(3-hydroxydodeca-6,10-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


(6E,10E)-3-Hydroxydodeca-6,10-dienoylcarnitine is an acylcarnitine. More specifically, it is an (6E,10E)-3-Hydroxydodeca-6,10-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E,10E)-3-Hydroxydodeca-6,10-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6E,10E)-3-Hydroxydodeca-6,10-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hydroxydodeca-6,8-dienoylcarnitine

3-[(4-hydroxydodeca-6,8-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


4-Hydroxydodeca-6,8-dienoylcarnitine is an acylcarnitine. More specifically, it is an 4-Hydroxydodeca-6,8-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxydodeca-6,8-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxydodeca-6,8-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxydodeca-4,6-dienoylcarnitine

3-[(2-hydroxydodeca-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C19H33NO5 (355.23586080000007)


2-Hydroxydodeca-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an 2-Hydroxydodeca-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxydodeca-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxydodeca-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-3-enoylcarnitine

3-(tridec-3-enoyloxy)-4-(trimethylazaniumyl)butanoate

C20H37NO4 (355.27224420000005)


Tridec-3-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-3-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-3-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-5-enoylcarnitine

3-(tridec-5-enoyloxy)-4-(trimethylazaniumyl)butanoate

C20H37NO4 (355.27224420000005)


Tridec-5-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-8-enoylcarnitine

3-(tridec-8-enoyloxy)-4-(trimethylazaniumyl)butanoate

C20H37NO4 (355.27224420000005)


Tridec-8-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-8-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-8-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(11E)-Tridec-11-enoylcarnitine

3-(Tridec-11-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C20H37NO4 (355.27224420000005)


(11E)-Tridec-11-enoylcarnitine is an acylcarnitine. More specifically, it is an (11E)-tridec-11-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11E)-Tridec-11-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11E)-Tridec-11-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-2-enoylcarnitine

3-(Tridec-2-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C20H37NO4 (355.27224420000005)


Tridec-2-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-2-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-2-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-4-enoylcarnitine

3-(tridec-4-enoyloxy)-4-(trimethylazaniumyl)butanoate

C20H37NO4 (355.27224420000005)


Tridec-4-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-4-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-4-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-6-enoylcarnitine

3-(Tridec-6-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C20H37NO4 (355.27224420000005)


Tridec-6-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-6-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-6-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(9E)-Tridec-9-enoylcarnitine

3-(Tridec-9-enoyloxy)-4-(trimethylazaniumyl)butanoic acid

C20H37NO4 (355.27224420000005)


(9E)-Tridec-9-enoylcarnitine is an acylcarnitine. More specifically, it is an (9E)-tridec-9-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9E)-Tridec-9-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9E)-Tridec-9-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-7-enoylcarnitine

3-(tridec-7-enoyloxy)-4-(trimethylazaniumyl)butanoate

C20H37NO4 (355.27224420000005)


Tridec-7-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-7-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-7-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Tridec-10-enoylcarnitine

3-(tridec-10-enoyloxy)-4-(trimethylazaniumyl)butanoate

C20H37NO4 (355.27224420000005)


Tridec-10-enoylcarnitine is an acylcarnitine. More specifically, it is an tridec-10-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Tridec-10-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine Tridec-10-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Azastene

1,6,6,10a,12a-Pentamethyl-2,3,3a,3b,4,6,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol

C23H33NO2 (355.25111580000004)


   

Cyanoketone

14-hydroxy-2,6,6,14,15-pentamethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-7-ene-4-carbonitrile

C23H33NO2 (355.25111580000004)


   

Cyprodime

17-(cyclopropylmethyl)-3,10-dimethoxy-17-azatetracyclo[7.5.3.0^{1,10}.0^{2,7}]heptadeca-2(7),3,5-trien-13-one

C22H29NO3 (355.2147324)


   

10H-Pyrido(3,2-b)(1,4)benzothiazine, 10-(2-(dibutylamino)ethyl)-

dibutyl(2-{9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaen-2-yl}ethyl)amine

C21H29N3S (355.20820740000005)


   

Dimethylsphingosine

2-(1-amino-2-hydroxyheptadec-3-en-1-yl)-2-hydroxypropanedial

C20H37NO4 (355.27224420000005)


   

Linoleylanilide

N-phenyloctadeca-9,12-dienamide

C24H37NO (355.2874992)


   

N-(4-Methoxy-3-phenethoxyphenethyl)-N-propylpropan-1-amine

N,N-Dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride

C23H33NO2 (355.25111580000004)


   

Nicanartine

2,6-di-tert-butyl-4-{3-[(pyridin-3-yl)methoxy]propyl}phenol

C23H33NO2 (355.25111580000004)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C26170 - Protective Agent > C275 - Antioxidant

   

1-(1-Methoxybutan-2-yl)-N-(4-methoxy-2-methylphenyl)-6-methyltriazolo[4,5-c]pyridin-4-amine

(+ -)-N-(2-Methyl-4-methoxyphenyl)-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo(4,5-c)pyridin-4-amine

C19H25N5O2 (355.200815)


   
   
   
   

Cyclobuxophylline O

Cyclobuxophylline O

C24H37NO (355.2874992)


   
   
   

Spirasine II

9-Hydroxyspiradine D

C22H29NO3 (355.2147324)


   
   
   
   
   
   
   

Antibiotic TAN 1057D

Antibiotic TAN 1057D

C13H25N9O3 (355.208026)


   

Laetispicine|N-isobutyl-11-(3,4-methylendioxyphenyl)-2E,4E,9E-undecatrienamide

Laetispicine|N-isobutyl-11-(3,4-methylendioxyphenyl)-2E,4E,9E-undecatrienamide

C22H29NO3 (355.2147324)


   

(E, E, E)-Piperstachine|Piperstachin|piperstachine

(E, E, E)-Piperstachine|Piperstachin|piperstachine

C22H29NO3 (355.2147324)


   
   
   

(6,7-dihydro-8,9-dihydroxy)-3-farnesylindole

(6,7-dihydro-8,9-dihydroxy)-3-farnesylindole

C23H33NO2 (355.25111580000004)


   
   
   

3,18-dioxo 20S-dimethylamino 1,4-pregnadiene

3,18-dioxo 20S-dimethylamino 1,4-pregnadiene

C23H33NO2 (355.25111580000004)


   

1-[(2E,4E)-11-(3,4-methylenedioxyphenyl)-2,4-undecadienoyl]pyrrolidine

1-[(2E,4E)-11-(3,4-methylenedioxyphenyl)-2,4-undecadienoyl]pyrrolidine

C22H29NO3 (355.2147324)


A natural product found in Piper boehmeriaefolium.

   

1-[(2E,10E)-11-(3,4-methylenedioxyphenyl)-2,10-undecadienoyl]pyrrolidine

1-[(2E,10E)-11-(3,4-methylenedioxyphenyl)-2,10-undecadienoyl]pyrrolidine

C22H29NO3 (355.2147324)


A natural product found in Piper boehmeriaefolium.

   
   
   
   
   
   
   

1-methyl-2-[7-hydroxy-(E)-9-tridecenyl]-4(1H)-quinolone

1-methyl-2-[7-hydroxy-(E)-9-tridecenyl]-4(1H)-quinolone

C23H33NO2 (355.25111580000004)


   

1-methyl-2-tetradecyl-4(1H)-quinolone

1-methyl-2-tetradecyl-4(1H)-quinolone

C24H37NO (355.2874992)


   

15-Cyanopuupehenol|15alpha-cyanopuupehenol

15-Cyanopuupehenol|15alpha-cyanopuupehenol

C22H29NO3 (355.2147324)


   

daphlongamine G|rel-(2aS,4aS,8S,9R,10aR,10bS,10cS)-2,2a,3,4,4a,5,7,8,9,10,10a,10b,11,12-tetradecahydro-2a-methoxy-8,10b-dimethyl-1H-9,10c-methanocyclopenta[1,8]azuleno[4,5-a]indolizine-1,13-dione

daphlongamine G|rel-(2aS,4aS,8S,9R,10aR,10bS,10cS)-2,2a,3,4,4a,5,7,8,9,10,10a,10b,11,12-tetradecahydro-2a-methoxy-8,10b-dimethyl-1H-9,10c-methanocyclopenta[1,8]azuleno[4,5-a]indolizine-1,13-dione

C22H29NO3 (355.2147324)


   

1-Hydroxymethylpyrrolizidine methyl 2-O-acetyl-2-isopropylmalate

1-Hydroxymethylpyrrolizidine methyl 2-O-acetyl-2-isopropylmalate

C18H29NO6 (355.19947740000003)


   

nakijinol B

nakijinol B

C22H29NO3 (355.2147324)


A natural product found in Dactylospongia elegans.

   
   
   
   
   

Pipercide

(2E,4E,10E)-11-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)undeca-2,4,10-trienamide

C22H29NO3 (355.2147324)


   

2-{2-[4[(2-Hydroxy-3-isopropylaminopropoxy)-benzyloxy]ethoxy}-propionic acid

2-{2-[4[(2-Hydroxy-3-isopropylaminopropoxy)-benzyloxy]ethoxy}-propionic acid

C18H29NO6 (355.19947740000003)


   

p-Hydroxypropoxyphene

p-Hydroxypropoxyphene

C22H29NO3 (355.2147324)


   

NA 20:2;O3

N-(3-Hydroxy-9Z-octadecenoyl) glycine

C20H37NO4 (355.27224420000005)


   

9-ethyl-3-[n-ethyl-n-(m-tolyl)hydrazonomethyl]carbazole

9-ethyl-3-[n-ethyl-n-(m-tolyl)hydrazonomethyl]carbazole

C24H25N3 (355.204837)


   

Solvent Violet 8

Solvent Violet 8

C24H25N3 (355.204837)


   

(2R)-2-{[6-(Benzyloxy)-9-isopropyl-9H-purin-2-YL]amino}butan-1-OL

(2R)-2-{[6-(Benzyloxy)-9-isopropyl-9H-purin-2-YL]amino}butan-1-OL

C19H25N5O2 (355.200815)


   

N-Ethyl-N-Isopropyl-3-Methyl-5-{[(2s)-2-(Pyridin-4-Ylamino)propyl]oxy}benzamide

N-Ethyl-N-Isopropyl-3-Methyl-5-{[(2s)-2-(Pyridin-4-Ylamino)propyl]oxy}benzamide

C21H29N3O2 (355.2259654)


   

10H-Pyrido(3,2-b)(1,4)benzothiazine, 10-(2-(dibutylamino)ethyl)-

10H-Pyrido(3,2-b)(1,4)benzothiazine, 10-(2-(dibutylamino)ethyl)-

C21H29N3S (355.20820740000005)


   
   

1-cyclopentyl-N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-5-oxo-3-pyrrolidinecarboxamide

1-cyclopentyl-N-[2-(3,4-dihydro-1H-isoquinolin-2-yl)ethyl]-5-oxo-3-pyrrolidinecarboxamide

C21H29N3O2 (355.2259654)


   
   

(3R)-3-hydroxy-2,3-dihydrotabersonine

(3R)-3-hydroxy-2,3-dihydrotabersonine

C21H27N2O3+ (355.2021572)


   

(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoate

(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoate

C24H35O2- (355.263691)


A tetracosahexaenoate that is the conjugate base of (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   

3,4-dimethylidenenonanedioylcarnitine

3,4-dimethylidenenonanedioylcarnitine

C18H29NO6 (355.19947740000003)


   

17-Hydroxy-4,4,10,13,17-pentamethyl-3-oxo-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-2-carbonitrile

17-Hydroxy-4,4,10,13,17-pentamethyl-3-oxo-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-2-carbonitrile

C23H33NO2 (355.25111580000004)


   
   
   
   
   
   
   
   
   
   
   

3-Hydroxydodeca-6,9-dienoylcarnitine

3-Hydroxydodeca-6,9-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

3-Hydroxydodeca-5,7-dienoylcarnitine

3-Hydroxydodeca-5,7-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

5-Hydroxydodeca-7,9-dienoylcarnitine

5-Hydroxydodeca-7,9-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

2-Hydroxydodeca-5,8-dienoylcarnitine

2-Hydroxydodeca-5,8-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

4-Hydroxydodeca-6,8-dienoylcarnitine

4-Hydroxydodeca-6,8-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

2-Hydroxydodeca-4,6-dienoylcarnitine

2-Hydroxydodeca-4,6-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

3-Hydroxydodeca-7,10-dienoylcarnitine

3-Hydroxydodeca-7,10-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

6-Hydroxydodeca-8,10-dienoylcarnitine

6-Hydroxydodeca-8,10-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

(6E,10E)-3-Hydroxydodeca-6,10-dienoylcarnitine

(6E,10E)-3-Hydroxydodeca-6,10-dienoylcarnitine

C19H33NO5 (355.23586080000007)


   

(9E,12E)-N-phenyloctadeca-9,12-dienamide

(9E,12E)-N-phenyloctadeca-9,12-dienamide

C24H37NO (355.2874992)


   

2-[(E)-1-amino-2-hydroxyheptadec-3-enyl]-2-hydroxypropanedial

2-[(E)-1-amino-2-hydroxyheptadec-3-enyl]-2-hydroxypropanedial

C20H37NO4 (355.27224420000005)


   

1-[(4E,10E)-11-(3,4-methylenedioxyphenyl)-4,10-undecadienoyl]pyrrolidine

1-[(4E,10E)-11-(3,4-methylenedioxyphenyl)-4,10-undecadienoyl]pyrrolidine

C22H29NO3 (355.2147324)


A natural product found in Piper boehmeriaefolium.

   

(3R,5R)-5-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]-1-methyl-3-pyrrolidinol

(3R,5R)-5-[2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethyl]-1-methyl-3-pyrrolidinol

C22H29NO3 (355.2147324)


   

1,1-Dimethyl-3-[3-(4-morpholinyl)propyl]-3-(1-naphthalenylmethyl)urea

1,1-Dimethyl-3-[3-(4-morpholinyl)propyl]-3-(1-naphthalenylmethyl)urea

C21H29N3O2 (355.2259654)


   

17-O-acetylnorajmaline(1+)

17-O-acetylnorajmaline(1+)

C21H27N2O3+ (355.2021572)


An indole alkaloid cation that is the conjugate acid of 17-O-acetylnorajmaline, obtained by protonation of the tertiary amino function. Major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

   

(-)-Minovincinine(1+)

(-)-Minovincinine(1+)

C21H27N2O3+ (355.2021572)


An ammonium ion resulting from the protonation of the tertiary amino group of (-)-minovincinine. The major species at pH 7.3.

   
   

Prostaglandin F1(1-)

Prostaglandin F1(1-)

C20H35O5- (355.248436)


   

(2E,4E,8E)-N-isobutyl-11-(3,4-methylenedioxyphenyl)undeca-2,4,8-trienamide

(2E,4E,8E)-N-isobutyl-11-(3,4-methylenedioxyphenyl)undeca-2,4,8-trienamide

C22H29NO3 (355.2147324)


A natural product found in Piper boehmeriaefolium.

   

9alpha,11alpha-Dihydroxy-15-oxoprostan-1-oate

9alpha,11alpha-Dihydroxy-15-oxoprostan-1-oate

C20H35O5- (355.248436)


   

(3R)-3-hydroxy-2,3-dihydrotabersoninium

(3R)-3-hydroxy-2,3-dihydrotabersoninium

C21H27N2O3+ (355.2021572)


An indole alkaloid cation that is the conjugate acid of (3R)-3-hydroxy-2,3-dihydrotabersonine, obtained by protonation of the tertiary amino group. Major species at pH 7.3.

   

2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-piperidin-1-ylethyl)acetamide

2-[(3R,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-piperidin-1-ylethyl)acetamide

C18H33N3O4 (355.2470938)


   

2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

2-[(3S,6aS,8R,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

C18H33N3O4 (355.2470938)


   

2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-piperidin-1-ylethyl)acetamide

2-[(3S,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-(2-piperidin-1-ylethyl)acetamide

C18H33N3O4 (355.2470938)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

2-[(2R,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2R,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(2S,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2S,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(2S,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2S,3S,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

2-[(3S,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

C18H33N3O4 (355.2470938)


   

2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

2-[(3R,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

C18H33N3O4 (355.2470938)


   

2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

2-[(3S,6aR,8R,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

C18H33N3O4 (355.2470938)


   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2S,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[2-(1-piperidinyl)ethylamino]ethyl]-3-oxanyl]propanamide

C18H33N3O4 (355.2470938)


   

2-[(2S,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2S,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(2S,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2S,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(2R,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2R,3S,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(2R,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2R,3R,6S)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(2R,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

2-[(2R,3R,6R)-3-[[(cyclopentylamino)-oxomethyl]amino]-2-(hydroxymethyl)-3,6-dihydro-2H-pyran-6-yl]-N-(2-methoxyethyl)acetamide

C17H29N3O5 (355.21071040000004)


   

2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

2-[(3R,6aS,8S,10aS)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

C18H33N3O4 (355.2470938)


   

2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

2-[(3R,6aR,8S,10aR)-3-hydroxy-1,2,3,4,6,6a,8,9,10,10a-decahydropyrano[2,3-c][1,5]oxazocin-8-yl]-N-[2-(1-piperidinyl)ethyl]acetamide

C18H33N3O4 (355.2470938)


   

(1R,5S)-7-[4-(2-methylphenyl)phenyl]-6-(3-pyridinylmethyl)-3,6-diazabicyclo[3.1.1]heptane

(1R,5S)-7-[4-(2-methylphenyl)phenyl]-6-(3-pyridinylmethyl)-3,6-diazabicyclo[3.1.1]heptane

C24H25N3 (355.204837)


   

[(1R)-1-(cyclopropylmethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1R)-1-(cyclopropylmethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol

C21H29N3O2 (355.2259654)


   

[(1S)-1-(cyclopropylmethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol

[(1S)-1-(cyclopropylmethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,3-azetidine]yl]methanol

C21H29N3O2 (355.2259654)


   

(1R,5S)-7-[4-(2-methylphenyl)phenyl]-6-(2-pyridinylmethyl)-3,6-diazabicyclo[3.1.1]heptane

(1R,5S)-7-[4-(2-methylphenyl)phenyl]-6-(2-pyridinylmethyl)-3,6-diazabicyclo[3.1.1]heptane

C24H25N3 (355.204837)


   

N(alpha)-acetyl-N(tele)-(1,4-dihydroxynonan-3-yl)-L-histidine

N(alpha)-acetyl-N(tele)-(1,4-dihydroxynonan-3-yl)-L-histidine

C17H29N3O5 (355.21071040000004)


   

(2S)-hydroxy[(9Z)-octadec-9-enoylamino]acetic acid

(2S)-hydroxy[(9Z)-octadec-9-enoylamino]acetic acid

C20H37NO4 (355.27224420000005)


   

10-Hydroxycoronaridine(1+)

10-Hydroxycoronaridine(1+)

C21H27N2O3+ (355.2021572)


A tertiary ammonium ion resulting from the protonation of the tertiary amino group of 10-hydroxycoronaridine. The major species at pH 7.3.

   

prostaglandin F1alpha (1-)

prostaglandin F1alpha (1-)

C20H35O5- (355.248436)


   

(5Z,9alpha,11alpha,15S)-9,11,15-trihydroxyprost-5-en-1-oate

(5Z,9alpha,11alpha,15S)-9,11,15-trihydroxyprost-5-en-1-oate

C20H35O5- (355.248436)


   

4-(Dimethylamino)-1-(2-hydroxyphenyl)-3-methyl-2-phenylbutan-2-yl propanoate

4-(Dimethylamino)-1-(2-hydroxyphenyl)-3-methyl-2-phenylbutan-2-yl propanoate

C22H29NO3 (355.2147324)


   

4-(Dimethylamino)-3-hydroxy-3-methyl-1,2-diphenylbutan-2-yl propanoate

4-(Dimethylamino)-3-hydroxy-3-methyl-1,2-diphenylbutan-2-yl propanoate

C22H29NO3 (355.2147324)


   

(3-Heptoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

(3-Heptoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C15H34NO6P (355.2123634)


   

2-Aminoethyl (3-decoxy-2-hydroxypropyl) hydrogen phosphate

2-Aminoethyl (3-decoxy-2-hydroxypropyl) hydrogen phosphate

C15H34NO6P (355.2123634)


   

2-(beta-Dipropylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido[3,4-a]indole

2-(beta-Dipropylaminopropionyl)-5,7-dimethyl-1,2,3,4-tetrahydropyrimido[3,4-a]indole

C22H33N3O (355.26234880000004)


   

methyl (2S,13bS,14aS,1R,4aR)-2-hydroxy-1,2,3,4,5,8,14,13b,14a,4a-decahydrobenz o[1,2-g]indolo[2,3-a]quinolizinecarboxylate

methyl (2S,13bS,14aS,1R,4aR)-2-hydroxy-1,2,3,4,5,8,14,13b,14a,4a-decahydrobenz o[1,2-g]indolo[2,3-a]quinolizinecarboxylate

C21H27N2O3+ (355.2021572)


   

15alpha-stemmadenine(1+)

15alpha-stemmadenine(1+)

C21H27N2O3 (355.2021572)


An ammonium ion resulting from the protonation of the tertiary amino group of 15alpha-stemmadenine. The major species at pH 7.3.

   

(+)-minovincinine(1+)

(+)-minovincinine(1+)

C21H27N2O3 (355.2021572)


An ammonium ion resulting from the protonation of the tertiary amino group of (+)-minovincinine. The major species at pH 7.3.

   

Tetracosahexaenoate

Tetracosahexaenoate

C24H35O2 (355.263691)


A polyunsaturated fatty acid anion that is the conjugate base of tetracosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

13,14-dihydroprostaglandin F2alpha(1-)

13,14-dihydroprostaglandin F2alpha(1-)

C20H35O5 (355.248436)


A prostaglandin carboxylic acid anion that is the conjugate base of 13,14-dihydroprostaglandin F2alpha, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   
   
   
   
   

(1r,5r,6s,11r,12s,14s,17s,20s,21s)-21-hydroxy-5-methyl-15-methylidene-7-oxa-10-azaheptacyclo[12.6.2.0¹,¹¹.0⁵,²⁰.0⁶,¹⁰.0¹²,¹⁷.0¹⁷,²¹]docosan-19-one

(1r,5r,6s,11r,12s,14s,17s,20s,21s)-21-hydroxy-5-methyl-15-methylidene-7-oxa-10-azaheptacyclo[12.6.2.0¹,¹¹.0⁵,²⁰.0⁶,¹⁰.0¹²,¹⁷.0¹⁷,²¹]docosan-19-one

C22H29NO3 (355.2147324)


   

6-amino-15-ethylidene-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

6-amino-15-ethylidene-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

C24H37NO (355.2874992)


   

methyl 14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate

methyl 14,18-dimethyl-12-azahexacyclo[10.6.1.1¹,⁴.0¹⁰,¹⁸.0¹⁵,¹⁹.0⁷,²⁰]icos-7(20)-ene-3-carboxylate

C23H33NO2 (355.25111580000004)


   

(1s,3r,6s,8r,11s,12s,15e,16s)-6-amino-15-ethylidene-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

(1s,3r,6s,8r,11s,12s,15e,16s)-6-amino-15-ethylidene-7,7,12,16-tetramethylpentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadecan-14-one

C24H37NO (355.2874992)


   

(1r,2r,5r,7s,8r,9r,10r,13r,17r)-11-ethyl-7-hydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,16-dione

(1r,2r,5r,7s,8r,9r,10r,13r,17r)-11-ethyl-7-hydroxy-13-methyl-6-methylidene-11-azahexacyclo[7.7.2.1⁵,⁸.0¹,¹⁰.0²,⁸.0¹³,¹⁷]nonadecane-4,16-dione

C22H29NO3 (355.2147324)


   

[(3r,3ar,3br,4r,8ar)-4-hydroxy-3-(2-hydroxypropan-2-yl)-2-oxo-hexahydro-3h-furo[3,2-a]pyrrolizin-3a-yl]methyl 3-methylbutanoate

[(3r,3ar,3br,4r,8ar)-4-hydroxy-3-(2-hydroxypropan-2-yl)-2-oxo-hexahydro-3h-furo[3,2-a]pyrrolizin-3a-yl]methyl 3-methylbutanoate

C18H29NO6 (355.19947740000003)


   

(1s,2s,3r,5r,6s,10s,13s)-13-methoxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-16(19)-ene-15,20-dione

(1s,2s,3r,5r,6s,10s,13s)-13-methoxy-2,6-dimethyl-8-azahexacyclo[11.5.1.1¹,⁵.0²,¹⁰.0³,⁸.0¹⁶,¹⁹]icos-16(19)-ene-15,20-dione

C22H29NO3 (355.2147324)


   

(2e,4e,10e)-11-(2h-1,3-benzodioxol-4-yl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

(2e,4e,10e)-11-(2h-1,3-benzodioxol-4-yl)-n-(2-methylpropyl)undeca-2,4,10-trienimidic acid

C22H29NO3 (355.2147324)